|
| |
Accueil (13041 entreprises) > Etats-Unis (2564 entreprises) > Pharmacie (87 entreprises) >
Merck & Co., Inc.
| Adresse du siège social: P.O. Box 100, One Merck Drive Whitehouse Station, NJ 08889 |  | Tel. 908-423-1000 Offres d'emploi, relations investisseurs: www.merck.com Bourse:  |
|
|
nom  photo produits comparer les prix |
Achetons local, éthique et au meilleur prix avec Ethishop ! |
|
|
EVALUATION « ÉTHIQUE » DE MERCK
, groupe
et filiales
[ ?] |
| Emploi: 16% des effectifs supprimés depuis 1998 |
| Environnement: 1 pollution(s) notable(s) |
| Délinquance: 3 acte(s) de délinquance financière ou commerciale |
| Evasion fiscale, comptes bancaires secrets, sociétés-écran: implanté dans 11 paradis financiers |
| Ventes: plus de 22 milliard(s) de dollars/euros par an |
| Benefice net: plus de 45 milliard(s) de dollars/euros de bénéfices cumulés depuis 1998 |
| Dirigeant: gagne 238 fois le salaire médian français (17808 euros/an) |
| Influence: 9 acte(s) de corruption directe ou lobbying |
| Publicité & marketing: 4 pratique(s) douteuse(s) |
|
|
Pertinence: activité & part de marché |
année | activité source |
| 2006 | Merck est le septième groupe pharmaceutique mondial. | Les Echos |
| 2006 | Merck vend 10% des vaccins achetés dans le monde. | Les Echos |
|
Implantations mondiales & production |
| année nom | photo fonction; rémunération source |
| 2002Lewent, Judy |  Directeur financier; salaire: 1.2 millions US$; stock-options: 4.74 millions US$; |
|
| année | pratique douteuse : image source |
| 2007 | Désinformation: Une comparaison des données internes de Merck en 2001 avec les résultats de deux essais cliniques rendus publics en 2004 et 2005 révèle « que la présentation de Merck quant au risque de décès lié au Vioxx chez des malades souffrant d'Alzheimer pourrait avoir été minimisée à dessein », selon un article du « Journal of the American Medical Association ». Merck avait volontairement retiré le Vioxx du marché en septembre 2004 à la suite d'une étude montrant que le médicament doublait le risque d'accidents cardio-vasculaires après dix-huit mois d'utilisation quotidienne. Le document interne a été obtenu dans le cadres des procès auxquels Merck est confronté au sujet du Vioxx.: | Les Echos |
| 2007 | Désinformation: In June 2005, U.S. National Public Radio's Snigdha Prakash reported, "New documents obtained by NPR suggest that even as Merck was making Vioxx into a bestseller, the company was putting pressure on independent doctors. The company's apparent aim: to keep them from discussing evidence of Vioxx's potential safety problems. The documents show that Merck exerted pressure not only on individual doctors, but also on several of the nation's top medical schools." NPR described Merck's campaign to recruit the physician Gurkirpal Singh of Stanford University as a Vioxx spokesperson. "Merck wanted Singh on board because he was a senior researcher on a seminal study of arthritis patients," reported Prakash. Starting in 1998, Merck cultivated Singh; the physician soon became a Vioxx booster, being paid $2,500 per speaking engagement by Merck. But in 2000, a study suggesting heart problems among Vioxx users worried Dr. Singh. He asked Merck for the data. "I wanted to know how many heart attacks, how many strokes, how many deaths were occurring in each one of the groups, and what were these actual number of patients at risk, and how many ended up having an event," he told NPR. Merck originally promised to share the information with Singh, but never did. Singh began including his concerns in his public presentations on Vioxx. Merck began closely tracking Dr. Singh's activities. According to NPR: Almost a dozen Merck executives were involved [in tracking Dr. Singh]. A senior regional executive who had supervised Singh's scientific handlers sent this Oct. 4, 2000, e-mail: "I have in excess of 80 e-mails pertaining to interactions with Dr. Singh from March 1999 to present. The following is my best recollection of what has happened. Because of the sensitive nature of the following, I strongly encourage you not to share with anyone unless they clearly have a need to know." As Singh's public criticisms of Vioxx continued ("He was now promoting Vioxx's rival, Celebrex," and "being paid by Pfizer," reported NPR. Merck decided to start calling his superiors at Stanford. Stanford medical professor James Fries told NPR, "I received a call from a medical director at Merck, stating that someone on my staff had been making wild and irresponsible public statements about the cardiovascular side effects of Vioxx." Fries said the Merck representative "hinted there would be repercussions for Fries and Stanford if Singh's statements didn't stop. He was left with the sense that Merck's financial support to Stanford was at risk." traduire : | Sourcewatc. |
| 2005 | Désinformation: In June 2005, the ad agency Ogilvy & Mather Worldwide launched the first promotional campaign ever for Merck - a $20 million, 6-month campaign with the slogan "Merck. Where patients come first." The campaign was planned before the company was forced to withdraw its popular painkiller Vioxx, and before evidence came to light that Merck not only ignored evidence that Vioxx caused heart complications, but also heavily marketed the drug. The major goal of the Merck promotional campaign was "to build emotional ties between Merck and consumers": One television commercial shows cute children reacting in charming confusion to requests to define "measles," "mumps" and "chicken pox." "Most kids today don't have a clue about diseases adults remember, thanks to Merck's scientists," a female announcer says, adding: "We've invested billions to research heart disease and asthma. Now we're trying to make Alzheimer's, diabetes and cancer history too." … Also, more than 40 percent of the ads in the campaign are being devoted to information about what Merck calls its access programs, which are efforts to provide some consumers with prescription drugs either free or at reduced prices. traduire : valeur: Merck. Where patients come first.; | Sourcewatc. |
| 2005 | Désinformation: Merck allegedly tried to censor vioxx critics. Merck hired Stanford University's Dr. Gurkirpal Singh in 1998 and paid him up to $2,500 for each talk he gave to other physicians about Vioxx. But when Singh became concerned about a 2000 study suggesting Vioxx increased the risk of heart attacks, Merck tracked Singh's public comments on Vioxx, eventually contacting his bosses at Stanford and hinting "there would be repercussions ... if Singh's statements didn't stop." Merck provides significant research funding to Stanford, a common arrangement between drug companies and universities. traduire : | NPR |
| 2005 | |  |
| 2005 | slogan: Merck. Where patients come
first.; | |
| 2004 | "APCO Worldwide is supporting Merck's PR efforts for the controversial" -- and deadly -- "arthritis drug Vioxx, which was found to increase heart attack risk in patients," reports O'Dwyer's. traduire : | Sourcewatc. |
|
|
| année | employés <> | impact social : pays source |
| 2005 | -7000 | Fermeture/Faillite: Merck will close 5 manufacturing plants, one research site and two preclinical development sites to trim costs by as much as $4 billion through 2010. About half of the job cuts will be in the U.S., Merck said. traduire : Etats-Unis | Bloomberg |
| 2003 | 62000 | | |
| 2002 | 78100 | | |
| 2001 | 69300 | | |
| 1999 | 62300 | | |
| 1998 | 57300 | | |
|
Impact sur l'environnement |
| année | délinquance financière | ventes | résultat | | rachat | source |
| 2006 |
Merck paye 2,3 milliards de dollars d'impôts, intérêts et pénalités d'impôts pour régler à l'amiable une enquête de l'administration fiscale des Etats-Unis portant sur l'enregistrement de ses brevets depuis 1993 dans des pays à faible fiscalité afin de payer moins d'impôt. |
| | | | | | Les Echos |
| 2005 |
Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said. traduire |
| | | | | | Canadian P. |
| 2003 |
| 22.49 | 6.83 | | | milliard(s) US$ | |
| 2002 |
| 51.79 | 7.15 | | | milliard(s) US$ | |
| 2001 |
| 47.72 | 7.28 | | | milliard(s) US$ | |
| 1999 |
| 32.71 | 5.89 | | | milliard(s) US$ | |
| 1998 |
| 26.9 | 5.25 | | | milliard(s) US$ | |
|
|
|
|
Annoncez aussi un documentaire, un livre ou un article ou commentez le profil de cette entreprise.
Objectif: faire connaître les activités de l'entreprise, améliorer l'exactitude de l'évaluation éthique, développer un réseau de surveillance.